Tethys picks up $25M for diabetes diagnostic

Tethys Bioscience, maker of a diagnostic test that indicates which patients are at the highest risk for developing Type 2 diabetes, has raised $25 million in a fourth round of funding. Based in Emeryville, Calif., the company is backed by Aeris Capital, Wasatch Advisors, Intel Capital, Kleiner Perkins Caufield & Byers and Mohr Davidow Ventures. It has raised about $80 million to date.